These results highlight the therapeutic potential of PHD targeting in AML and imply that PHD inhibition may compromise AML while counteracting AML-induced suppression of normal hematopoiesis and the negative impact of chemotherapy. This evidence concerns the gene PDC and acute myeloid leukemia.